Pharmaceutical Ads account for 11-12% of National TV Spend:
The FDA crackdown puts an estimated $4B in direct-to-consumer ads in Fourth Quarter 2025 at risk, as well as the national networks that air them and the media agencies that buy timeslots for the ads.
Last week, the FDA announced a crackdown on drug advertising, saying many ads fail to present a fair balance between a product’s risks and benefits. Beyond sending warning letters to Big Pharma, the FDA sent 100 “cease-and-desist” letters specifically targeting the deceptive use of social media and digital channels, where companies often use influencers to promote products while concealing or minimizing safety risks.
Pharmaceutical companies spent just under $7B on National TV over the past year, representing about 11.6% of total ad dollars that flowed to national broadcast and cable networks in 2024. (1)(2)
Pharma advertising – which grew over 10% in the past year alone, with a boost from weight management drugs – has grown significantly since 1997, when the FDA relaxed rules that allowed drug advertisers to briefly summarize a product’s risks. Those minimal safety risk disclosures are brief enough to fit into a 30- or 60-second ad. Linear TV networks typically skew to older audiences and still pull in big bucks from pharmaceutical brands: NBC ($203.1 million), ABC ($174.6 million), and CBS ($148.4 million) inthe past year.
The main drug industry lobby – PhRMA – may sue over the proposed policy change. The courts would then have to decide whether drug advertisements from a freedom of speech standpoint have actually harmed public health.
*(1) EDO Ad EnGage – 9/2024-9/2025
(2) Barron’s
(3) Media research company Guideline